ArticleAlzheimer's research & therapy2026
T1-weighted/T2-weighted ratio reflects microstructural changes in Alzheimer's disease.
Article in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe T1-weighted/T2-weighted ratio (T1w/T2w-ratio) has been considered as a relatively simple neuroimaging approach to map myelin content in the aging and diseased brain. However, we hypothesize that any process affecting the tissue microstructural integrity also contributes to observed changes in the T1w/T2w-ratio. Here, we aim to evaluate the ability of T1w/T2w-ratio to detect microstructural changes, specifically within the paradigm of Alzheimer's disease (AD).
methodsPostmortem in-situ T1-weighted and T2-weighted MRI scans of 27 control and 51 AD brain donors were processed into standardized T1w/T2w-ratio images and parcellated into cortical regions according to the brainnetome atlas. Using an identical pipeline, antemortem MRI scans of 9 AD cases were processed. Immunohistochemical staining and digital quantification were performed for amyloid-beta (4G8), phosphorylated tau (AT8), neuro-axonal damage (NfL), myelin (PLP), microglia (IBA1), and iron (Meguro) in 9 cortical regions. Data was analysed using linear mixed models.
resultsWhole cortex T1w/T2w-ratio was 15% lower in AD compared to controls and was 13% lower in the hippocampus of typical AD compared to atypical AD clinical phenotypes. Additionally, a strong correlation was found between antemortem and postmortem T1w/T2w-ratios (r = 0.85). Whole-brain associations between T1w/T2w-ratio and histological changes were found in both control and AD patients: T1w/T2w-ratio associated with myelin density (Controls: β = 0.229; AD: β = 0.312) and microglia density (Controls: β=-0.090; AD: β=-0.496). In AD but not in controls, T1w/T2w-ratio associated with amyloid-beta (β = 0.233), phosphorylated tau (β=-0.220), and neuro-axonal damage (β = 0.170). Iron load showed contrasting associations in controls and AD (Controls: β=-0.359; AD: β = 0.154).
conclusionThe findings in this study suggest that the T1w/T2w-ratio is mainly associated with myelin density in healthy controls, but is a broader indicator of microstructural integrity in Alzheimer's disease, where it additionally largely associates with accumulation of amyloid-beta, phosphorylated tau and neuro-axonal damage. Therefore, the T1w/T2w-ratio is not a myelin-specific marker in AD, but could be a valuable neuroimaging tool for tracking longitudinal microstructural changes when interpreted alongside established AD pathology biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.